TY - JOUR
T1 - RELEVENT Trial
T2 - Phase II Trial of Ramucirumab, Carboplatin, and Paclitaxel in Previously Untreated Thymic Carcinoma/B3 Thymoma With Area of Carcinoma
AU - Imbimbo, Martina
AU - Vitali, Milena
AU - Fabbri, Alessandra
AU - Ottaviano, Margaret
AU - Pasello, Giulia
AU - Petrini, Iacopo
AU - Palmieri, Giovannella
AU - Berardi, Rossana
AU - Zucali, Paolo
AU - Ganzinelli, Monica
AU - Marabese, Mirko
AU - Broggini, Massimo
AU - Marino, Mirella
AU - Trama, Annalisa
AU - Rulli, Eliana
AU - Hollander, Lital
AU - Pruneri, Giancarlo
AU - Torri, Valter
AU - Garassino, Marina Chiara
N1 - Copyright © 2018 Elsevier Inc. All rights reserved.
PY - 2018/9
Y1 - 2018/9
N2 - Thymic epithelial tumors are rare malignancies. Thymic carcinoma represents about 20% of all thymic epithelial tumors and has aggressive behavior, with a greater tendency to metastatic spread. Thymic carcinoma is often diagnosed in advanced stages for which systemic treatment is the main therapeutic option. The association of chemotherapy and antiangiogenic agents in the first-line setting has never been investigated in this very rare cancer. However, preclinical and clinical evidence has suggested that inhibition of angiogenesis could be beneficial. The RELEVENT trial is a multicenter, open-label, single-arm, phase II study aimed at investigating the activity and safety of ramucirumab combined with paclitaxel and carboplatin in chemotherapy-naive patients affected by thymic carcinoma or B3 thymoma with area of carcinoma. The primary endpoint of the trial is the overall response rate. Progression-free survival, overall survival, and safety are secondary endpoints. Patient-reported outcomes will be collected at each visit. The mutational status of a subset of genes, polymorphisms, and selected micro-RNA expression will be evaluated.
AB - Thymic epithelial tumors are rare malignancies. Thymic carcinoma represents about 20% of all thymic epithelial tumors and has aggressive behavior, with a greater tendency to metastatic spread. Thymic carcinoma is often diagnosed in advanced stages for which systemic treatment is the main therapeutic option. The association of chemotherapy and antiangiogenic agents in the first-line setting has never been investigated in this very rare cancer. However, preclinical and clinical evidence has suggested that inhibition of angiogenesis could be beneficial. The RELEVENT trial is a multicenter, open-label, single-arm, phase II study aimed at investigating the activity and safety of ramucirumab combined with paclitaxel and carboplatin in chemotherapy-naive patients affected by thymic carcinoma or B3 thymoma with area of carcinoma. The primary endpoint of the trial is the overall response rate. Progression-free survival, overall survival, and safety are secondary endpoints. Patient-reported outcomes will be collected at each visit. The mutational status of a subset of genes, polymorphisms, and selected micro-RNA expression will be evaluated.
U2 - 10.1016/j.cllc.2018.06.005
DO - 10.1016/j.cllc.2018.06.005
M3 - Article
C2 - 30033090
VL - 19
SP - e811-e814
JO - Clinical Lung Cancer
JF - Clinical Lung Cancer
SN - 1525-7304
IS - 5
ER -